→
Charles River Laboratories (CRL) has a market cap of $7.52B and a current price of $156.82, reflecting a slight increase of 0.51%. Despite recent earnings beats, including a Q1 2026 EPS of $2.06 against an estimate of $1.96, the company's revenue growth is stagnating at just 0.11% YoY, raising concerns about long-term growth prospects. With a P/S ratio of 1.87 and a P/B of 2.68, the stock appears fairly valued but lacks strong momentum.
Investors should hold CRL for now, given its current valuation metrics and mixed growth outlook.
If Charles River Laboratories can improve its revenue growth from the current 0.11%, it could see a revaluation of its stock price closer to its 52-week high of $228.88. Additionally, the positive analyst consensus, with 15 out of 24 analysts rating it as a 'Buy' or 'Strong Buy', supports a potential upside in investor sentiment.
The company's negative ROE of -5.74% and lackluster revenue growth may indicate underlying operational inefficiencies. Furthermore, the stock's beta of 1.43 suggests higher volatility, which could deter conservative investors amid a challenging market environment.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates CRL as Neutral. Investors should hold CRL for now, given its current valuation metrics and mixed growth outlook.
The company's negative ROE of -5.74% and lackluster revenue growth may indicate underlying operational inefficiencies. Furthermore, the stock's beta of 1.43 suggests higher volatility, which could deter conservative investors amid a challenging market environment.
If Charles River Laboratories can improve its revenue growth from the current 0.11%, it could see a revaluation of its stock price closer to its 52-week high of $228.88. Additionally, the positive analyst consensus, with 15 out of 24 analysts rating it as a 'Buy' or 'Strong Buy', supports a potential upside in investor sentiment.
Charles River Laboratories (CRL) has a market cap of $7.52B and a current price of $156.82, reflecting a slight increase of 0.51%. Despite recent earnings beats, including a Q1 2026 EPS of $2.06 against an estimate of $1.96, the company's revenue growth is stagnating at just 0.11% YoY, raising concerns about long-term growth prospects. With a P/S ratio of 1.87 and a P/B of 2.68, the stock appears fairly valued but lacks strong momentum.
Charles River Laboratories (CRL) has a market cap of $7.52B and a current price of $156.82, reflecting a slight increase of 0.51%. Despite recent earnings beats, including a Q1 2026 EPS of $2.06 against an estimate of $1.96, the company's revenue growth is stagnating at just 0.11% YoY, raising concerns about long-term growth prospects. With a P/S ratio of 1.87 and a P/B of 2.68, the stock appears fairly valued but lacks strong momentum. Our overall verdict is Neutral.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for CRL at helmterminal.dev/analyze/CRL, updated continuously during US market hours. No signup required.